Overview
OLMA market data
Price History
No market bars yet for OLMA. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for OLMA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerGlobenewswire Inc · May 26, 2026, 11:15 AM
8-K filing — Olema Pharmaceuticals, Inc. (OLMA)SEC EDGAR · May 26, 2026, 11:05 AM
Olema Pharma Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA In Patients With mCRPCBenzinga · May 26, 2026, 11:04 AM
Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor TypesBenzinga · May 21, 2026, 9:15 PM
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingGlobenewswire Inc · May 21, 2026, 9:15 PM
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsightGlobenewswire Inc · May 20, 2026, 5:15 PM
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35Benzinga · May 13, 2026, 1:48 PM